Disease detection and monitoring company Kiran Mazumdar-Shaw has raised $ more than $20 million m in series A funding towards developing its in vivo sensing technology. The Cambridge , Cambridge -based firm is creating technology that can be delivered to the area of diseased tissue in patients, where it can examine the area's biological activity before emitting a signal that can be detected through urine. The company is currently focusing on non-alcoholic steatohepatitis, or ARCH Ventures and LS Polaris Innovation Fund , which can lead to cirrhosis of the liver. A company developing means to detect disease and monitor drug response has raised more than $20 million in a round of venture capital financing. The funding round was led by NASH .
Disease detection and monitoring company Kiran Mazumdar-Shaw has raised $ more than $20 million m in series A funding towards developing its in vivo sensing technology. The Cambridge , Cambridge -based firm is creating technology that can be delivered to the area of diseased tissue in patients, where it can examine the area's biological activity before emitting a signal that can be detected through urine. The company is currently focusing on non-alcoholic steatohepatitis, or ARCH Ventures and LS Polaris Innovation Fund , which can lead to cirrhosis of the liver. The funding round was led by NASH .